RecruitingPhase 1NCT03739411
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients With Gliomas
Sponsor
Susan Chang
Enrollment
140 participants
Start Date
Dec 9, 2015
Study Type
INTERVENTIONAL
Conditions
Summary
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Eligibility
Min Age: 19 Years
Inclusion Criteria14
- For Participants in Cohort 1: Histologically proven glioma who have evidence of evaluable disease based on a prior magnetic resonance (MR) scan.
- For Participants in Cohort 2: Histologically proven glioma who will be undergoing treatment.
- To be included in the study all subjects must also meet the following criteria:
- Participants must be > 18 years old and with a life expectancy > 12 weeks.
- Participants must have a Karnofsky performance status of ≥ 60.
- Participants must have adequate renal function (creatinine < 1.5 mg/dL) before starting therapy. This tests must be performed within 60 days prior to Hyperpolarized Imaging scan.
- Participants must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate the imaging examination or any disease that will obscure toxicity or dangerously alter response to the imaging agent.
- Participants must not have New York Heart Association (NYHA) Grade II or greater congestive heart failure
- Participants must not have a history of myocardial infarction or unstable angina within 12 months prior to study enrollment.
- This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. Minorities will actively be recruited to participate. No exclusion to this study will be based on race.
- Participants must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must sign an authorization for the release of their protected health information.
- Participants may not be known to be human immunodeficiency virus (HIV)-positive. HIV testing is not required for study participation.
- Participants must not have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.
- Participants must not be pregnant or breast feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of Hyperpolarized Imaging scan. Effective contraception (men and women) must be used in subjects of child-bearing potential.
Exclusion Criteria1
- \. Participants must be excluded from participating in this study if they are not able to comply with study and/or follow-up procedures.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONHyperpolarized Carbon C 13 Pyruvate
Given IV
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
RADIATIONRadiation Therapy
Undergo radiation therapy for cancer outside of this study.
DRUGChemotherapy
Undergo chemotherapy for cancer outside of this study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03739411
Related Trials
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT063441301 location
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NCT064969712 locations
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NCT063295701 location
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT0553813079 locations
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT073265662 locations